TKNO Alpha Teknova, Inc.

NEUTRAL Impact: 2/10 8-K
Horizon immediate Filed Jun 1, 2026 Processed 3d 22h ago SEC 0001850902-26-000011
8-K context-dependent: Items 5.02

Price Chart

Loading chart...

Executive Summary

Alpha Teknova filed an 8-K reporting that board member Irene Davis will not stand for re-election and will retire at the 2026 Annual Meeting, citing personal reasons with no disagreement with the company. The board reduced its size from eight to seven directors and appointed existing member Ms. Demski to the Nominating and Corporate Governance Committee. The filing also reports the results of the 2026 Annual Meeting, where all director nominees were elected and Grant Thornton LLP was ratified as auditor with overwhelming shareholder support.

Actionable Insight

This filing is purely administrative with no material financial or strategic implications. Monitor future filings for any changes in board composition or committee assignments, but no trading action is warranted based on this 8-K.

Key Facts

  • Director Irene Davis notified the company on May 27, 2026 of her decision not to stand for re-election and to retire from the board effective at the 2026 Annual Meeting.
  • Davis's retirement is due to personal and professional interests and does not arise from any disagreement with the board or company.
  • Board reduced size from eight to seven directors, and Class II directors from three to two, effective June 1, 2026.
  • Existing board member Ms. Demski was appointed to the Nominating and Corporate Governance Committee to fill the vacancy.
  • At the June 1, 2026 Annual Meeting, 47,821,520 shares (89.20% of outstanding) were represented.
  • Directors J. Matthew Mackowski and Brett Robertson were elected with 43.7M and 44.0M votes for, respectively.
  • Ratification of Grant Thornton LLP as auditor passed with 47.75M votes for, 2,167 against, and 65,809 abstentions.

Financial Impact

No financial impact — routine board governance and shareholder vote matters.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
75% bullish (12 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001850902-26-000011
Document: 0001850902-26-000011-index-headers.html0001850902-26-000011
Document: 0001850902-26-000011-index.html0001850902-26-000011
Document: 0001850902-26-000011.txt0001850902-26-000011
4 reports for TKNO
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TKNO — sortable, filterable
Type Now
Jun 1, 2026
3d ago
8-K
NEUTRAL ★ 2/10
awaiting T+20
May 6, 2026
29d ago
Press Release
BULLISH ★ 7/10
$4.00 $5.13▲ +28.25%▲ +25.11%$4.61 (+15.37%)
Apr 22, 2026
6w ago
Press Release
NEUTRAL ★ 3/10
$3.03 $3.70▲ +22.11%▲ +17.48%$4.61 (+52.31%)
Mar 6, 2026
13w ago
Insider Cluster
BULLISH ★ 6/10
$2.11 $3.12▲ +47.87%▲ +49.91%$4.61 (+118.72%)
Showing 4 of 4

US Market Status

Market Open — Closes in 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access